Arvinas, Inc. (ARVN) stock
ARVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.76−0.06 (-0.81%)
Close on Nov 18, 2026Market cap $442.34MP/E 42.3Yield –
Arvinas revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Arvinas's revenue for the twelve months ending Jun 30, 2026 was $316.70M, down 15.0% year over year. For fiscal 2025 it was $262.60M, down 0.3% from the year before. The highest annual figure on record is $263.40M in fiscal 2024.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $262.60M | -0.3% |
| FY2024 | Dec 31, 2024 | $263.40M | +235.5% |
| FY2023 | Dec 31, 2023 | $78.50M | -40.3% |
| FY2022 | Dec 31, 2022 | $131.40M | +145.1% |
| FY2021 | Dec 31, 2021 | $53.60M | +106.9% |
| FY2020 | Dec 31, 2020 | $25.90M | -39.8% |
| FY2019 | Dec 31, 2019 | $43.00M | +200.2% |
| FY2018 | Dec 31, 2018 | $14.32M | +89.0% |
| FY2017 | Dec 31, 2017 | $7.58M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $249.70M | +1014.7% |
| Q1 FY2026 | Mar 31, 2026 | $15.60M | -91.7% |
| Q4 FY2025 | Dec 31, 2025 | $9.50M | -84.0% |
| Q3 FY2025 | Sep 30, 2025 | $41.90M | -59.1% |
| Q2 FY2025 | Jun 30, 2025 | $22.40M | -70.7% |
| Q1 FY2025 | Mar 31, 2025 | $188.80M | +646.2% |
| Q4 FY2024 | Dec 31, 2024 | $59.20M | +71.1% |
| Q3 FY2024 | Sep 30, 2024 | $102.40M | +87.9% |
| Q2 FY2024 | Jun 30, 2024 | $76.50M | +135.4% |
| Q1 FY2024 | Mar 31, 2024 | $25.30M | -33.1% |
| Q3 FY2023 | Sep 30, 2023 | $34.60M | +4.2% |
| Q2 FY2023 | Jun 30, 2023 | $54.50M | +61.2% |
| Q1 FY2023 | Mar 31, 2023 | $32.50M | +22.6% |
| Q4 FY2022 | Dec 31, 2022 | $37.80M | +13.9% |
| Q3 FY2022 | Sep 30, 2022 | $33.20M | +257.0% |
| Q2 FY2022 | Jun 30, 2022 | $33.80M | +514.5% |
| Q1 FY2022 | Mar 31, 2022 | $26.50M | +381.8% |
| Q4 FY2021 | Dec 31, 2021 | $33.20M | +425.7% |
| Q3 FY2021 | Sep 30, 2021 | $9.30M | +22.4% |
| Q2 FY2021 | Jun 30, 2021 | $5.50M | -4.3% |
| Q1 FY2021 | Mar 31, 2021 | $5.50M | -11.9% |
| Q4 FY2020 | Dec 31, 2020 | $6.32M | +29.1% |
| Q3 FY2020 | Sep 30, 2020 | $7.60M | -74.7% |
| Q2 FY2020 | Jun 30, 2020 | $5.75M | +43.1% |
| Q1 FY2020 | Mar 31, 2020 | $6.24M | +55.4% |
| Q4 FY2019 | Dec 31, 2019 | $4.89M | +42.2% |
| Q3 FY2019 | Sep 30, 2019 | $30.05M | +790.3% |
| Q2 FY2019 | Jun 30, 2019 | $4.02M | +18.1% |
| Q1 FY2019 | Mar 31, 2019 | $4.02M | -2.2% |
| Q4 FY2018 | Dec 31, 2018 | $3.44M | +33.7% |
| Q3 FY2018 | Sep 30, 2018 | $3.38M | +102.2% |
| Q2 FY2018 | Jun 30, 2018 | $3.40M | +103.7% |
| Q1 FY2018 | Mar 31, 2018 | $4.11M | +146.2% |
| Q4 FY2017 | Dec 31, 2017 | $2.57M | – |
| Q3 FY2017 | Sep 30, 2017 | $1.67M | – |
| Q2 FY2017 | Jun 30, 2017 | $1.67M | – |
| Q1 FY2017 | Mar 31, 2017 | $1.67M | – |
See a number that looks wrong?